At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 196 target
Drug / intervention
NWY001 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05979155Phase 1RecruitingMonitorUpdated 23mo ago · Completion was 5mo agoSlow Enrollment
Monitor
A Multicenter, Non-randomized, Open-label, Multiple-Dose Phase I Study of NWY001, in Subjects With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating NWY001 for Advanced Solid Tumor. Currently recruiting, targeting 196 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20242025202620272028
First PostedAug 2023
Enrollment StartJan 2024
Primary CompletionJan 2026
TodayJul 2026
Study CompletionMay 2028
First PostedAug 7, 2023
Enrollment StartJan 5, 2024
Primary CompletionJan 1, 2026
Study CompletionMay 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.9 years ago
Interventions
NWY001biological
Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
NWY001biological
Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.